<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350128</url>
  </required_header>
  <id_info>
    <org_study_id>PT001002</org_study_id>
    <nct_id>NCT01350128</nct_id>
  </id_info>
  <brief_title>PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine an optimal dose and dosing regimen of
      PT001 MDI for further evaluation in later stage studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate efficacy relative to placebo of PT001
      MDI in patients with moderate to severe chronic obstructive pulmonary disease (COPD) within
      the range of doses evaluated in this protocol. To this end, each dose of PT001 MDI will be
      compared to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>Day 7 ( -1 hour, -30 min, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 5.5 hours, 6.5 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours)</time_frame>
    <description>FEV1 AUC0-12 following chronic dosing (1 week), normalized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Highest value of FEV1 post-dose minus baseline on Day 1 (baseline-adjusted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action ( ≥10% Improvement in FEV1) on Day 1</measure>
    <time_frame>Day 1 (15 min, 30 min, 1 hour, 2 hours)</time_frame>
    <description>Time to onset of action ( ≥10% improvement in FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving at Least 12% Improvement in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of subjects achieving at least 12% improvement in FEV1 (relative to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from baseline in Inspiratory Capacity (IC) on Day 1 (mean of 1 and 2 hours post-dose minus baseline on Day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning pre-dose FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in IC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-hour Post-dose Trough FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in 12-hour post-dose trough FEV1</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium Bromide HFA Inhalation Aerosol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ipratropium Bromide HFA Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PT001 Placebo MDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT001 MDI (Dose 1)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 2)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 3)</arm_group_label>
    <arm_group_label>PT001 MDI (Dose 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium Bromide HFA Inhalation Aerosol</intervention_name>
    <description>Taken as 2 inhalations of the 17 µg per actuation strength MDI QID</description>
    <arm_group_label>Ipratropium Bromide HFA Inhalation Aerosol</arm_group_label>
    <other_name>Atrovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Matching placebo to PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>May 8, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2017</results_first_posted>
  <disposition_first_submitted>May 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 24, 2013</disposition_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 9 US sites from May-October 2011. Entire period of study participation per subject was a maximum of 15 weeks. Planned target enrollment of 84 subjects.</recruitment_details>
      <pre_assignment_details>This was a chronic dosing study (7 days), 3-period, 6-treatment, incomplete block, crossover study. Each subject received 3 of 6 possible treatments; each treatment period was separated by a washout period 7-28 days. By-treatment sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects Randomized</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 36 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="49">Glycopyrronium Metered Dose Inhaler</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 18 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 9 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 4.6 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI BID</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Atrovent HFA 34 µg BID</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) Population includes all subjects who were randomized, received at least 1 dose of study treatment, and had both baseline and post-baseline efficacy data for that treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>ITT Population</title>
          <description>ITT Population includes all subjects who were randomized, received at least 1 dose of study treatment, and had both baseline and post-baseline efficacy data for that treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-12</title>
        <description>FEV1 AUC0-12 following chronic dosing (1 week), normalized.</description>
        <time_frame>Day 7 ( -1 hour, -30 min, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 5.5 hours, 6.5 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours)</time_frame>
        <population>Modified Intent to Treat (MITT) Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12</title>
          <description>FEV1 AUC0-12 following chronic dosing (1 week), normalized.</description>
          <population>Modified Intent to Treat (MITT) Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.477" lower_limit="1.418" upper_limit="1.537"/>
                    <measurement group_id="O2" value="1.497" lower_limit="1.437" upper_limit="1.556"/>
                    <measurement group_id="O3" value="1.443" lower_limit="1.385" upper_limit="1.501"/>
                    <measurement group_id="O4" value="1.514" lower_limit="1.456" upper_limit="1.572"/>
                    <measurement group_id="O5" value="1.465" lower_limit="1.405" upper_limit="1.524"/>
                    <measurement group_id="O6" value="1.323" lower_limit="1.263" upper_limit="1.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Day 1</title>
        <description>Highest value of FEV1 post-dose minus baseline on Day 1 (baseline-adjusted)</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Day 1</title>
          <description>Highest value of FEV1 post-dose minus baseline on Day 1 (baseline-adjusted)</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.245" spread="0.0252" lower_limit="0.195" upper_limit="0.295"/>
                    <measurement group_id="O2" value="0.221" spread="0.0247" lower_limit="0.172" upper_limit="0.270"/>
                    <measurement group_id="O3" value="0.181" spread="0.0256" lower_limit="0.130" upper_limit="0.232"/>
                    <measurement group_id="O4" value="0.204" spread="0.0206" lower_limit="0.153" upper_limit="0.255"/>
                    <measurement group_id="O5" value="0.250" spread="0.0258" lower_limit="0.198" upper_limit="0.301"/>
                    <measurement group_id="O6" value="0.071" spread="0.0251" lower_limit="0.021" upper_limit="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action ( ≥10% Improvement in FEV1) on Day 1</title>
        <description>Time to onset of action ( ≥10% improvement in FEV1)</description>
        <time_frame>Day 1 (15 min, 30 min, 1 hour, 2 hours)</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action ( ≥10% Improvement in FEV1) on Day 1</title>
          <description>Time to onset of action ( ≥10% improvement in FEV1)</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>% of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset within 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving at Least 12% Improvement in FEV1 on Day 1</title>
        <description>Proportion of subjects achieving at least 12% improvement in FEV1 (relative to baseline)</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population: This includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving at Least 12% Improvement in FEV1 on Day 1</title>
          <description>Proportion of subjects achieving at least 12% improvement in FEV1 (relative to baseline)</description>
          <population>MITT Population: This includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="58.70"/>
                    <measurement group_id="O3" value="52.27"/>
                    <measurement group_id="O4" value="60.98"/>
                    <measurement group_id="O5" value="77.78"/>
                    <measurement group_id="O6" value="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC on Day 1</title>
        <description>Peak change from baseline in Inspiratory Capacity (IC) on Day 1 (mean of 1 and 2 hours post-dose minus baseline on Day 1)</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC on Day 1</title>
          <description>Peak change from baseline in Inspiratory Capacity (IC) on Day 1 (mean of 1 and 2 hours post-dose minus baseline on Day 1)</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" spread="0.0379" lower_limit="0.165" upper_limit="0.316"/>
                    <measurement group_id="O2" value="0.276" spread="0.0377" lower_limit="0.201" upper_limit="0.351"/>
                    <measurement group_id="O3" value="0.185" spread="0.0374" lower_limit="0.111" upper_limit="0.259"/>
                    <measurement group_id="O4" value="0.187" spread="0.0380" lower_limit="0.111" upper_limit="0.262"/>
                    <measurement group_id="O5" value="0.252" spread="0.0396" lower_limit="0.173" upper_limit="0.330"/>
                    <measurement group_id="O6" value="0.040" spread="0.0385" lower_limit="-0.036" upper_limit="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose FEV1 on Day 7</title>
        <description>Change from baseline in morning pre-dose FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose FEV1 on Day 7</title>
          <description>Change from baseline in morning pre-dose FEV1</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" spread="0.0246" lower_limit="0.039" upper_limit="0.136"/>
                    <measurement group_id="O2" value="0.075" spread="0.0245" lower_limit="0.027" upper_limit="0.124"/>
                    <measurement group_id="O3" value="0.010" spread="0.0248" lower_limit="-0.039" upper_limit="0.059"/>
                    <measurement group_id="O4" value="0.084" spread="0.0247" lower_limit="0.035" upper_limit="0.133"/>
                    <measurement group_id="O5" value="-0.088" spread="0.0256" lower_limit="-0.138" upper_limit="-0.037"/>
                    <measurement group_id="O6" value="-0.043" spread="0.0246" lower_limit="-0.092" upper_limit="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Day 7</title>
        <description>Peak change from baseline in FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Day 7</title>
          <description>Peak change from baseline in FEV1</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="0.0303" lower_limit="0.181" upper_limit="0.302"/>
                    <measurement group_id="O2" value="0.224" spread="0.0300" lower_limit="0.164" upper_limit="0.284"/>
                    <measurement group_id="O3" value="0.223" spread="0.0307" lower_limit="0.162" upper_limit="0.285"/>
                    <measurement group_id="O4" value="0.238" spread="0.0308" lower_limit="0.176" upper_limit="0.300"/>
                    <measurement group_id="O5" value="0.225" spread="0.0307" lower_limit="0.164" upper_limit="0.287"/>
                    <measurement group_id="O6" value="0.070" spread="0.0305" lower_limit="0.009" upper_limit="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC on Day 7</title>
        <description>Peak change from baseline in IC</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC on Day 7</title>
          <description>Peak change from baseline in IC</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.213" spread="0.0416" lower_limit="0.130" upper_limit="0.295"/>
                    <measurement group_id="O2" value="0.189" spread="0.0411" lower_limit="0.107" upper_limit="0.271"/>
                    <measurement group_id="O3" value="0.161" spread="0.0424" lower_limit="0.077" upper_limit="0.245"/>
                    <measurement group_id="O4" value="0.192" spread="0.0426" lower_limit="0.107" upper_limit="0.277"/>
                    <measurement group_id="O5" value="0.191" spread="0.0424" lower_limit="0.106" upper_limit="0.275"/>
                    <measurement group_id="O6" value="-0.029" spread="0.0419" lower_limit="-0.112" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12-hour Post-dose Trough FEV1 on Day 7</title>
        <description>Change from baseline in 12-hour post-dose trough FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
        <group_list>
          <group group_id="O1">
            <title>PT001 MDI 36 µg BID</title>
            <description>PT001 MDI 36 µg BID.</description>
          </group>
          <group group_id="O2">
            <title>PT001 MDI 18 µg BID</title>
            <description>PT001 MDI 18 µg BID.</description>
          </group>
          <group group_id="O3">
            <title>PT001 MDI 9 µg BID</title>
            <description>PT001 MDI 9 µg BID</description>
          </group>
          <group group_id="O4">
            <title>PT001 MDI 4.6 µg BID</title>
            <description>PT001 MDI 4.6 µg BID.</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
            <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI BID</title>
            <description>Placebo MDI BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-hour Post-dose Trough FEV1 on Day 7</title>
          <description>Change from baseline in 12-hour post-dose trough FEV1</description>
          <population>MITT Population includes subjects who completed at least 2 treatment periods, with minimally 1 pre-dose assessment on Day 7 for each of those 2 treatment periods with no protocol deviations believed to have a potential impact on efficacy results.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0313" lower_limit="-0.045" upper_limit="0.080"/>
                    <measurement group_id="O2" value="0.079" spread="0.0304" lower_limit="0.018" upper_limit="0.139"/>
                    <measurement group_id="O3" value="0.004" spread="0.0306" lower_limit="-0.057" upper_limit="0.065"/>
                    <measurement group_id="O4" value="0.077" spread="0.0307" lower_limit="0.016" upper_limit="0.139"/>
                    <measurement group_id="O5" value="-0.041" spread="0.0311" lower_limit="-0.103" upper_limit="0.021"/>
                    <measurement group_id="O6" value="-0.054" spread="0.0316" lower_limit="-0.117" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.</time_frame>
      <desc>Safety population included all participants who received at least one dose of investigational drug and had safety data available; participants were included in safety population according to the investigational drug received</desc>
      <group_list>
        <group group_id="E1">
          <title>PT001 MDI 36 µg BID</title>
          <description>PT001 MDI 36 µg BID.</description>
        </group>
        <group group_id="E2">
          <title>PT001 MDI 18 µg BID</title>
          <description>PT001 MDI 18 µg BID.</description>
        </group>
        <group group_id="E3">
          <title>PT001 MDI 9 µg BID</title>
          <description>PT001 MDI 9 µg BID</description>
        </group>
        <group group_id="E4">
          <title>PT001 MDI 4.6 µg BID</title>
          <description>PT001 MDI 4.6 µg BID.</description>
        </group>
        <group group_id="E5">
          <title>Ipratropium Bromide HFA Inhalation Aerosol</title>
          <description>Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.</description>
        </group>
        <group group_id="E6">
          <title>Placebo BID</title>
          <description>Placebo BID.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

